Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT

Area of Science:

• Pharmacology and Medicinal Chemistry
• Oncology
• Biotechnology

Background:

• Conventional anti-proliferative cancer therapies often lack specificity, leading to significant side effects due to insufficient differentiation between normal and malignant cells.
• Selective tumor-targeting strategies are crucial for enhancing anticancer drug efficacy and reducing normal tissue toxicity.
• Emerging approaches like Antibody-Directed Enzyme Prodrug Therapy (ADEPT), Gene-Directed Enzyme Prodrug Therapy (GDEPT), and Prodrug Monotherapy (PMT) offer promising solutions.

Purpose of the Study:

• To review recent advancements in the design and biological evaluation of prodrugs for selective cancer therapies.
• To highlight novel glycosidic prodrugs based on CC-1065 and duocarmycins for ADEPT, GDEPT, and PMT applications.
• To assess the therapeutic window and cytotoxic potential of these advanced prodrugs.

Main Methods:

• Review of literature on prodrug design and biological evaluation for ADEPT, GDEPT, and PMT.
• Discussion of novel glycosidic prodrugs derived from natural antibiotics CC-1065 and duocarmycins.
• Analysis of therapeutic window and cytotoxicity data (IC50 values).

Main Results:

• Novel glycosidic prodrugs based on CC-1065 and duocarmycins demonstrate a significant therapeutic window, up to one million.
• These prodrugs correspond to highly potent cytotoxic agents with IC50 values as low as 110 fM.
• The reviewed prodrug strategies enable selective release of cytotoxic agents at the tumor site.

Conclusions:

• Advanced prodrug strategies, including ADEPT, GDEPT, and PMT, offer enhanced efficacy and reduced toxicity in cancer treatment.
• Novel glycosidic prodrugs exhibit exceptional therapeutic potential due to their high potency and wide therapeutic window.
• These developments represent a significant step forward in the targeted delivery of cytotoxic agents for improved cancer therapy.